Amphastar Pharmaceuticals Inc Dossier
Qualitative Analysis
Business overview
Amphastar Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products. The company also produces insulin active pharmaceutical ingredients (API). Amphastar operates primarily in the United States, with additional manufacturing and research facilities in China and France. Its finished products are widely used in hospital and urgent care clinical settings, distributed through group purchasing organizations and drug wholesalers. Key proprietary products include BAQSIMI, a dry nasal spray for severe hypoglycemia, and Primatene MIST, an over-the-counter epinephrine inhaler.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Amphastar is executing a fundamental business model transformation to shift its pipeline away from commodity generics toward high-margin proprietary and biosimilar products. The company projects that proprietary and biosimilar products will represent 85% of its pipeline by 2026 (specifically targeting 50% proprietary, 35% biosimilar, and only 15% generic), compared to 2021 when generics comprised 63% of the pipeline.
Expected impact: Designed to capture higher gross margins, establish stronger competitive moats, and reduce vulnerability to price erosion seen in the standard generic market.
A multi-year infrastructure investment to quadruple production capacity at the company's Rancho Cucamonga, California headquarters. The expansion includes constructing a new state-of-the-art production plant featuring enhanced automation and advanced technologies to support critical medication production and pipeline candidates.
Expected impact: Provides greater manufacturing flexibility, agility, and quality control while reinforcing supply chain resilience by keeping all finished pharmaceutical manufacturing within the United States.
Expanding the commercial footprint of BAQSIMI (nasal glucagon) into over 25 international markets. Amphastar assumed full global commercialization and distribution responsibilities for BAQSIMI at the beginning of 2025, transitioning all related revenues into direct product sales.
Expected impact: Aims to capture a larger share of the emergency glucagon market, targeting peak annual sales of $250 million to $275 million and contributing $2.00 to $2.50 in incremental adjusted EPS at peak.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
Acquisition of the worldwide rights to BAQSIMI, a non-invasive nasal glucagon for severe hypoglycemia. This transaction served as a cornerstone for Amphastar's strategic pivot from complex generics toward high-margin branded specialties.
Financial impact: Transformed the company's revenue profile, with BAQSIMI growing to represent 26% of total revenues by 2025 ($185 million in annual sales) and lifting overall gross margins.
Strategic Partnerships
Strengthens Amphastar's proprietary peptide pipeline by securing exclusive development, manufacturing, and commercialization rights in the US and Canada for three novel peptide candidates targeting high-value oncology and ophthalmology indications.
Terms: Amphastar made an immediate commitment of $6.0 million ($0.75 million earnest money and $5.25 million upfront). The agreement includes up to $42.0 million in development milestones, up to $225.0 million in sales milestones, and 5% royalties on net sales (capped at $60.0 million per product). Total potential payments over the lifetime of the agreement could reach $453.0 million.